A review analyzed targeted molecular agents as a significant therapeutic shift in psoriasis treatment. These include first-, second-, and third-generation biologics and small-molecule treatments, offering unprecedented efficacy in clearing moderate to severe psoriasis. New steroid-free topicals are also emerging for limited areas of involvement, marking an era of more personalized treatment options targeting various elements of the immune system.

Recent medications target immune components and molecular signaling pathways, particularly the IL-17/23 axis. These treatments are effectively managing systemic inflammation and keratinocyte proliferation, crucial in psoriatic disease. Emerging treatments like tapinarof and roflumilast offer novel mechanisms for reducing skin inflammation and improving psoriasis symptoms. The latest biologic, bimekizumab, has shown high efficacy, blocking both IL-17A and IL-17F subunits. The challenge now, researchers concluded, is to fine-tune treatment choice based on individual factors like speed of onset, comorbidities, and ease of access, aiming for personalized medicine in psoriasis treatment.

Reference: Swift D. New Targeted Molecular Agents Tailor Psoriasis Treatment. MedPage Today. Updated March 8, 2024. Accessed March 29, 2024. https://www.medpagetoday.com/spotlight/aad-psoriasis/109077